Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 8/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658051 | 0.89 | BLM (0.63) | TAS2R14ARBLMSLC22A12 | |
| SCHEMBL14289402 | 0.86 | AR (0.59) | AR | |
| SCHEMBL18187538 | 0.86 | AR (0.59) | TAS2R14ARBLMSLC22A12 | |
| SCHEMBL2980069 | 0.86 | AR (0.59) | AR | |
| SCHEMBL324379 | 0.86 | AR (0.56) | TAS2R14ARBLMSLC22A12 | |
| SCHEMBL16823496 | 0.84 | TAS2R14 (0.53) | TAS2R14ARBLMSLC22A12 | |
| SCHEMBL9682036 | 0.84 | MAPT (0.65) | TAS2R14ARSLC22A12 | |
| SCHEMBL15032263 | 0.84 | BLM (0.56) | TAS2R14ARBLM | |
| SCHEMBL5664793 | 0.84 | AR (0.55) | TAS2R14AR | |
| SCHEMBL9430893 | 0.84 | AR (0.63) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733170-A1 | A METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) | Oncternal Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2872482-B1 | A METHOD OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) | ONCTERNAL THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3068784-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073767-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| EP-1831164-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067401-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | TAS2R14 3024/4885AR 788/4885BLM 2351/4885 |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | TAS2R14 4036/4885AR 2738/4885BLM 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.